Literature DB >> 3969217

Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.

L Figà-Talamanca, C Gualandi, L Di Meo, G Di Battista, G Neri, F Lo Russo.   

Abstract

Hyperthermia, with no signs of any underlying infection, may occur in the course of neuroleptic malignant syndrome, fatal catatonia, heat stroke, or malignant hyperthermia. We describe hyperthermia as a complication after discontinuance of antiparkinsonian treatment with levodopa/carbidopa and bromocriptine. Impaired nigrostriatal, hypothalamic, and mesolimbic dopaminergic functions could be involved in pathogenesis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3969217     DOI： 10.1212/wnl.35.2.258

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  9 in total

1.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

2.  Apomorphine in malignant syndrome due to levodopa withdrawal.

Authors:  U Bonuccelli; P Piccini; G U Corsini; A Muratorio
Journal:  Ital J Neurol Sci       Date:  1992-03

3.  Selective tropism of a neurotropic coronavirus for ependymal cells, neurons, and meningeal cells.

Authors:  M Tardieu; O Boespflug; T Barbé
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

Review 4.  When should levodopa therapy be initiated in patients with Parkinson's disease?

Authors:  Irene A C Halkias; Ihtsham Haq; Zhigao Huang; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Neuroleptic malignant syndrome: a review.

Authors:  R A O'Brien; G B Young
Journal:  Can Fam Physician       Date:  1989-05       Impact factor: 3.275

Review 6.  A critical review of the pathophysiology of dysautonomia following traumatic brain injury.

Authors:  Ian J Baguley; Roxana E Heriseanu; Ian D Cameron; Melissa T Nott; Shameran Slewa-Younan
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

7.  Hyperthermic syndromes and impairment of the dopaminergic system: a clinical study.

Authors:  L Figà-Talamanca; C Gualandi
Journal:  Ital J Neurol Sci       Date:  1989-02

Review 8.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

9.  Malignant syndrome in Parkinson's disease without dopaminergic drug withdrawal.

Authors:  C J Suresh Chandran
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.